Armored’
-
Health
‘Armored’ CAR T Cells Highly Active in Lymphoma After Prior CAR-T Failure
Oncology/Hematology > Lymphoma — 81% of patients responded to CD19-targeting, IL-18-secreting therapy by Mike Bassett, Staff Writer, MedPage Today May…
Read More »